The US Food and Drug Administration has cast doubt on the efficacy of Capricor Therapeutics' experimental drug for Duchenne muscular dystrophy, a rare and fatal muscle wasting disease. In briefing documents released ahead of an advisory committee hearing, the agency questioned whether the treatment, called CAP 1002, provides meaningful clinical benefits. The development marks another setback for the drug, which has faced regulatory hurdles despite promising early stage data.
The FDA has raised significant concerns about Capricor Therapeutics' experimental treatment for Duchenne muscular dystrophy, just days before a pivotal advisory committee meeting scheduled for June 26. In briefing documents published on Monday, the agency questioned the clinical meaningfulness of CAP 1002, a cell based therapy designed to slow muscle degeneration in patients with the rare genetic disorder.
The FDA's skepticism centers on the drug's primary endpoint in its Phase 3 HOPE 3 trial. While Capricor reported statistically significant improvements in upper limb function among treated patients, the agency argued these changes may not translate to meaningful real world benefits. The trial also failed to meet its secondary endpoint of improving cardiac function, a critical concern given Duchenne's life threatening impact on heart muscle.
DISCUSSION (0)